The British Journal of Rheumatology, Vol 37, 1172-1176, Copyright © 1998 by British Society for Rheumatology
E Toussirot, NU Nguyen, G Dumoulin, J Regnard and D Wendling
OBJECTIVE: Low bone mass, vertebral osteopenia and fractures have been
described in patients with ankylosing spondylitis (AS), but the aetiology
of this osteoporosis (OP) remains unknown. Insulin-like growth factor-I
(IGF-I), a bone-promoting peptide, may be considered as reflecting
osteoblast function as well as its main binding protein, insulin-like
growth factor binding protein-3 (IGFBP-3). Both were found to be decreased
in post-menopausal women and male patients with idiopathic OP. In this
study, we aimed to measure the circulating IGF-I and IGFBP-3 in AS
patients. METHODS: Thirty-three AS patients were compared to 23 healthy
controls. Bone mineral density (dual X-ray absorptiometry) was measured at
the spine and the femoral neck. We determined the serum levels of growth
hormone (GH), insulin, glycaemia, and the IGF-I and IGFBP-3 serum
concentrations. RESULTS: A lowered lumbar spine bone mineral density was
found in the AS group (AS: 0.946 g/cm2, controls: 1.02 g/cm2; P = 0.05). AS
patients had a higher glycaemia than controls, but results were in the
normal range. There were no significant differences in the mean values for
GH and insulin. Mean IGF-I serum levels were 218.3 ng/ml (+/-72.4) in
patients and 212.1 (+/-71.1) in controls (P = 0.75). The serum
concentrations of IGFBP-3 were significantly lower in AS (3.29+/-0.6
microg/ml) than in healthy subjects (3.63+/-0.6 microg/ml; P = 0.05). There
was a negative correlation between the serum IGFBP-3 concentration and
erythrocyte sedimentation rate (r = -0.39; P = 0.025). CONCLUSIONS: Since
IGFBP-3 is an important cofactor for IGF-I and modulates its
bioavailability and activity in bone, these data suggest that osteoblast
cell function could be impaired in AS. Inflammation could play a role in
this IGFBP- 3/IGF-I axis involvement. However, further studies are
warranted to determine the role of the other growth factors and their
binding proteins in the OP of AS.
ORIGINAL PAPERS
Insulin-like growth factor-I and insulin-like growth factor binding protein-3 serum levels in ankylosing spondylitis
Department of Rheumatology, University Hospital J. Minjoz, Besancon, France.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Toussirot, N. U. Nguyen, G. Dumoulin, F. Aubin, J.-P. Cedoz, and D. Wendling Relationship between growth hormone-IGF-I-IGFBP-3 axis and serum leptin levels with bone mass and body composition in patients with rheumatoid arthritis Rheumatology, January 1, 2005; 44(1): 120 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsumoto and T. Tsurumoto Inappropriate serum levels of IGF-I and IGFBP-3 in patients with rheumatoid arthritis Rheumatology, March 1, 2002; 41(3): 352 - 353. [Full Text] [PDF]
|
|